– Ramp-up of innovative drugs with higher margin and extensive product mix.
– Strong pipeline supporting future growth with higher R&D expense.
– Continue the expansion of distribution network covering more hospitals and cities.
About the author
Eurus Zhou Phillip Securities (HK)
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.